Gene Transfer Technologies Market Report 2026

The gene transfer technologies market size has grown rapidly in recent years. It will grow from $4.54 billion in 2025 to $5.19 billion in 2026 at a compound annual growth rate (CAGR) of 14.3%. The growth in the historic period can be attributed to advancements in molecular biology research, increasing funding for genetic research, expansion of recombinant protein production, early clinical success of gene therapies, growth of academic and research laboratories.

The gene transfer technologies market size is expected to see rapid growth in the next few years. It will grow to $8.77 billion in 2030 at a compound annual growth rate (CAGR) of 14%. The growth in the forecast period can be attributed to increasing demand for personalized medicine, rising investments in gene therapy pipelines, expansion of regenerative medicine applications, growing adoption of precision genetic engineering tools, increasing collaboration between biotech and pharma companies. Major trends in the forecast period include increasing use of viral vector gene delivery systems, rising adoption of non-viral gene transfer methods, growing focus on high-efficiency transfection technologies, expansion of ex vivo gene modification techniques, enhanced emphasis on scalable gene delivery platforms.

The rising prevalence of genetic disorders is expected to drive the growth of the gene transfer technologies market in the coming years. Genetic disorders are caused by alterations in one or more genes or chromosomes that disrupt normal biological functions. The increasing prevalence of these disorders is largely due to enhanced diagnosis and reporting, aging populations, and improved survival rates of affected infants through better clinical care. Gene transfer technologies allow for targeted delivery and correction of defective genes, support the creation of gene therapies and precision treatments, and expand diagnostic and research opportunities. For example, in February 2025, the World Health Organization, a UN health agency based in Switzerland, reported that over 300 million people worldwide live with rare diseases, with around 70% of cases originating in childhood. As a result, the rising prevalence of genetic disorders is fueling the growth of the gene transfer technologies market.

Major companies in the gene transfer technologies market are investing in advanced manufacturing platforms and integrated contract development and manufacturing organization (CDMO) services to accelerate cell and gene therapy development, enhance scalability, and ensure regulatory compliance. Integrated CDMO services provide comprehensive solutions by combining product development, process optimization, and large-scale manufacturing within a single provider, thereby streamlining biopharmaceutical production and reducing time-to-market. For instance, in October 2025, AGC Biologics, a US-based biopharmaceutical contract manufacturer, launched a dedicated Cell and Gene Therapy Business Division to strengthen its end-to-end development and manufacturing capabilities for plasmid DNA, viral vectors, and cell therapies. The initiative aims to optimize production, improve process efficiency, and offer customized solutions that facilitate faster transitions from clinical to commercial scale. By leveraging expertise across multiple platforms, this approach fosters innovation in gene transfer, shortens therapeutic timelines, and advances the global cell and gene therapy sector.

In July 2024, Genezen, a US-based CDMO, acquired uniQure’s commercial gene therapy operations for an undisclosed sum. This acquisition enables Genezen to expand its commercial gene therapy capabilities and accelerate market access for advanced treatments. uniQure, based in the Netherlands, is a biopharmaceutical company dedicated to developing and commercializing gene therapies for patients with serious genetic disorders.

Major companies operating in the gene transfer technologies market are Thermo Fisher Scientific, Merck KGaA, Evonik Industries, Lonza Group AG, Agilent Technologies Inc., Charles River Laboratories, Sartorius AG, Bio-Techne Corporation, Takara Bio Inc., Aldevron, Regenxbio Inc., CureVac AG, OriGene Technologies, Precision NanoSystems, 4D Molecular Therapeutics, Synthego Corporation, Addgene, Acuitas Therapeutics, Transposagen Biopharmaceuticals, Vigene Biosciences.

North America was the largest region in the gene transfer technologies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene transfer technologies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gene transfer technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the gene transfer technologies market by increasing costs of imported reagents, viral vectors, laboratory instruments, and precision manufacturing equipment used in gene delivery and transfection workflows. Research institutions and biopharmaceutical companies in North America and Europe are most affected due to reliance on specialized imported inputs, while Asia-Pacific faces cost pressure on export-oriented biotech manufacturing. These tariffs can increase research and development expenses and slow procurement cycles. However, they are also encouraging domestic production of reagents and instruments, strengthening regional biotech supply chains and fostering local innovation ecosystems.

The gene transfer technologies market research report is one of a series of new reports that provides gene transfer technologies market statistics, including gene transfer technologies industry global market size, regional shares, competitors with a gene transfer technologies market share, detailed gene transfer technologies market segments, market trends and opportunities, and any further data you may need to thrive in the gene transfer technologies industry. This gene transfer technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gene transfer technologies involve advanced approaches for introducing foreign genetic material into cells to alter or control their genetic composition. These technologies are essential for developing gene therapies, conducting genetic research, and producing recombinant proteins. By allowing precise genetic modifications, they aid in treating inherited disorders and advancing personalized medicine.

The primary products of gene transfer technologies include reagents, kits and assays, consumables, instruments, and others. Reagents, kits, and assays are critical components that facilitate and monitor the gene transfer process by ensuring efficient delivery and expression of genetic material in target cells. Different modes include viral, retrovirus, adenovirus, adeno-associated virus, non-viral, electroporation, and gene gun, while key methods consist of in vivo, ex vivo, and in vitro. Major applications cover gene therapy, personalized medicine, regenerative medicine, and vaccine development, with main end-users including academic and research institutes, biopharmaceutical companies, and contract research organizations.

The gene transfer technologies market consists of revenues earned by entities by providing services such as cell line development services, regulatory and compliance support services, and custom assay development services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gene transfer technologies market also includes sales of electroporation devices, microinjection systems, cell culture media, and bioreactors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.